Cargando…

PD-1(+)CD8(+) T Cells Proximal to PD-L1(+)CD68(+) Macrophages Are Associated with Poor Prognosis in Pancreatic Ductal Adenocarcinoma Patients

SIMPLE SUMMARY: The current methods for assessing tumor microenvironments (TMEs) using cellular markers and cell density-based assays do not identify the primitive phenotypes of single cells with multilineage selectivity or functional or cellular spatial information in tissues. Here, we combined the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Xiaobao, Wang, Guanzheng, Song, Yue, Zhuang, Tongtao, Li, Yifei, Xie, Yujie, Fei, Xuefeng, Zhao, Yanan, Xu, Dakang, Hu, Yiqun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000394/ https://www.ncbi.nlm.nih.gov/pubmed/36900182 http://dx.doi.org/10.3390/cancers15051389

Ejemplares similares

Targeting Proliferating Tumor-Infiltrating Macrophages Facilitates Spatial Redistribution of CD8(+) T Cells in Pancreatic Cancer
por: Yang, Xiaobao, et al.
Publicado: (2022)

Restored CD8(+)PD-1(+) T Cells Facilitate the Response to Anti-PD-1 for Patients With Pancreatic Ductal Adenocarcinoma
por: Zhu, Qian, et al.
Publicado: (2022)

Identification of calcium and integrin-binding protein 1 as a reprogrammed glucose metabolism mediator to restrict immune cell infiltration in the stromal compartment of pancreatic ductal adenocarcinoma
por: Ma, Junrui, et al.
Publicado: (2023)

Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma
por: Diana, Angela, et al.
Publicado: (2016)

PD-1-Positive Tumor-Associated Macrophages Define Poor Clinical Outcomes in Patients With Muscle Invasive Bladder Cancer Through Potential CD68/PD-1 Complex Interactions
por: Jiang, Li-Ren, et al.
Publicado: (2021)

Increased CD86 but Not CD80 and PD-L1 Expression on Liver CD68(+) Cells during Chronic HBV Infection
por: Said, Elias A., et al.
Publicado: (2016)

Dynamic alteration and prognostic significance of tumor‐associated CD68(+) and CD68(+)PD‐L1(−) macrophages in muscle‐invasive bladder cancer treated with neoadjuvant chemotherapy
por: Wu, Jie, et al.
Publicado: (2022)

Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma
por: Ma, Ke, et al.
Publicado: (2020)

CD8(+)PD-1(+) to CD4(+)PD-1(+) ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers
por: Duchemann, Boris, et al.
Publicado: (2022)

Decreased blood CD4+PD-1+ and CD8+PD-1+ T cells in psoriatic patients with and without arthritis
por: Bartosińska, Joanna, et al.
Publicado: (2018)

Variable density of CD8+ and CD25+ programmed cell death-1 (PD-1) ligand (PD-L1) CD4+ T cells within the tumor microenvironment causes differential responses to the PD-1/PD-L1 blockade
por: Wu, Si-Pei, et al.
Publicado: (2015)

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
por: Escors, David, et al.
Publicado: (2022)

Circulating memory PD-1(+)CD8(+) T cells and PD-1(+)CD8(+)T/PD-1(+)CD4(+)T cell ratio predict response and outcome to immunotherapy in advanced gastric cancer patients
por: Liu, Jiang, et al.
Publicado: (2023)

Accumulation of CD5(+)CD19(+) B lymphocytes expressing PD-1 and PD-1L in hypertrophied pharyngeal tonsils
por: Wlasiuk, Paulina, et al.
Publicado: (2015)

A Potential Inhibitory Profile of Liver CD68(+) Cells during HCV Infection as Observed by an Increased CD80 and PD-L1 but Not CD86 Expression
por: Said, Elias A., et al.
Publicado: (2016)

PD-L1 expression is a prognostic factor in subgroups of gastric cancer patients stratified according to their levels of CD8 and FOXP3 immune markers
por: Ying, Le, et al.
Publicado: (2018)

Circulating Exhausted PD-1(+)CD39(+) Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis Blockade
por: Martinez-Gomez, Carlos, et al.
Publicado: (2022)

Intra-Tumoral CD8+ T-Cell Infiltration and PD-L1 Positivity in Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma
por: Golesworthy, Bryn, et al.
Publicado: (2022)

Prognostic value of PD‑L1 expression and CD68 macrophages in tumor nest of patients with primary gastric cancer
por: Zou, Yunlian, et al.
Publicado: (2023)

Prognostic role and correlation of CA9, CD31, CD68 and CD20 with the desmoplastic stroma in pancreatic ductal adenocarcinoma
por: Diana, Angela, et al.
Publicado: (2016)

PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1(hi)CD39(+) CD4 T cells
por: Balança, Camille-Charlotte, et al.
Publicado: (2021)

Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients
por: Geng, Ruixuan, et al.
Publicado: (2023)

Retinoblastoma Is Characterized by a Cold, CD8+ Cell Poor, PD-L1− Microenvironment, Which Turns Into Hot, CD8+ Cell Rich, PD-L1+ After Chemotherapy
por: Miracco, Clelia, et al.
Publicado: (2021)

Different Induction of PD-L1 (CD274) and PD-1 (CD279) Expression in THP-1-Differentiated Types 1 and 2 Macrophages
por: Lai, Chun-Yi, et al.
Publicado: (2021)

CD70 and PD‐L1 (CD274) co‐expression predicts poor clinical outcomes in patients with pleural mesothelioma
por: Inaguma, Shingo, et al.
Publicado: (2023)

CD72/CD100 and PD-1/PD-L1 markers are increased on T and B cells in HIV-1(+) viremic individuals, and CD72/CD100 axis is correlated with T-cell exhaustion
por: Correa-Rocha, Rafael, et al.
Publicado: (2018)

Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80
por: Cassady, Kaniel, et al.
Publicado: (2018)

Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28
por: Zhang, Chaoxu, et al.
Publicado: (2020)

PD-1/PD-L1 Control of Antigen-Specifically Activated CD4 T-Cells of Neonates
por: Majer, Christiane, et al.
Publicado: (2023)

Prognostic Role of CD68(+) and CD163(+) Tumour-Associated Macrophages and PD-L1 Expression in Oral Squamous Cell Carcinoma: A Meta-Analysis
por: Chohan, Mohammed Haseeb, et al.
Publicado: (2023)

Brain metastasis PD-L1 and CD8 expression is dependent on primary tumor type and its PD-L1 and CD8 status
por: Camy, Florian, et al.
Publicado: (2020)

Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression
por: Lin, Ziying, et al.
Publicado: (2019)

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy
por: Zuazo, Miren, et al.
Publicado: (2020)

PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas
por: Xie, Wei, et al.
Publicado: (2022)

Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA
por: Zhang, Wenxin, et al.
Publicado: (2023)

Staphylococcus aureus convert neonatal conventional CD4(+) T cells into FOXP3(+) CD25(+) CD127(low) T cells via the PD-1/PD-L1 axis
por: Rabe, Hardis, et al.
Publicado: (2014)

BCL9 regulates CD226 and CD96 checkpoints in CD8(+) T cells to improve PD-1 response in cancer
por: Feng, Mei, et al.
Publicado: (2021)

Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy
por: Niemeijer, Anna-Larissa Nadia, et al.
Publicado: (2020)

PD1(Hi) CD8(+) T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma
por: Ma, Jiaqiang, et al.
Publicado: (2019)

Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy
por: Zuazo, Miren, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5pegqmae98kh94pg0btbbqi1jc